These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 4528634)

  • 1. Continuous subcutaneous administration of deferoxamine in patients with iron overload.
    Propper RD; Cooper B; Rufo RR; Nienhuis AW; Anderson WF; Bunn HF; Rosenthal A; Nathan DG
    N Engl J Med; 1977 Aug; 297(8):418-23. PubMed ID: 882111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of food and nutrients on iron overload: what do we know so far?
    Omena J; Curioni C; Cople-Rodrigues CDS; Citelli M
    Eur J Clin Nutr; 2021 Dec; 75(12):1771-1780. PubMed ID: 33712721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications.
    Kontoghiorghes GJ; Kolnagou A; Kontoghiorghe CN; Mourouzidis L; Timoshnikov VA; Polyakov NE
    Medicines (Basel); 2020 Jul; 7(8):. PubMed ID: 32751493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically approved iron chelators influence zebrafish mortality, hatching morphology and cardiac function.
    Hamilton JL; Hatef A; Imran ul-Haq M; Nair N; Unniappan S; Kizhakkedathu JN
    PLoS One; 2014; 9(10):e109880. PubMed ID: 25329065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance.
    Modell B; Khan M; Darlison M; Westwood MA; Ingram D; Pennell DJ
    J Cardiovasc Magn Reson; 2008 Sep; 10(1):42. PubMed ID: 18817553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A risk-benefit assessment of iron-chelation therapy.
    Porter JB
    Drug Saf; 1997 Dec; 17(6):407-21. PubMed ID: 9429839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desferrioxamine in ocular siderosis: a long-term electrophysiological evaluation.
    Declercq SS
    Br J Ophthalmol; 1980 Aug; 64(8):626-9. PubMed ID: 7426580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine.
    Marsh MN; Holbrook IB; Clark C; Shaffer JL
    Postgrad Med J; 1981 Sep; 57(671):582-4. PubMed ID: 7329898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload.
    Janka GE; Möhring P; Helmig M; Haas RJ; Betke K
    Eur J Pediatr; 1981 Nov; 137(3):285-90. PubMed ID: 7318841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early iron overload in beta-thalassaemia major: when to start chelation therapy?
    Fargion S; Taddei MT; Gabutti V; Piga A; Di Palma A; Capra L; Fontanelli G; Avanzini A
    Arch Dis Child; 1982 Dec; 57(12):929-33. PubMed ID: 7181522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival and desferrioxamine in thalassaemia major.
    Modell B; Letsky EA; Flynn DM; Peto R; Weatherall DJ
    Br Med J (Clin Res Ed); 1982 Apr; 284(6322):1081-4. PubMed ID: 6802413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent.
    Bowern N; Ramshaw IA; Clark IA; Doherty PC
    J Exp Med; 1984 Nov; 160(5):1532-43. PubMed ID: 6333485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemoglobinopathies. The pathophysiology of beta-thalassaemia major.
    Modell CB
    J Clin Pathol Suppl (R Coll Pathol); 1974; 8():12-8. PubMed ID: 4536357
    [No Abstract]   [Full Text] [Related]  

  • 14. Iron-mediated oxidative stress in erythrocytes.
    Rice-Evans C; Baysal E
    Biochem J; 1987 May; 244(1):191-6. PubMed ID: 3663112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current concepts in the management of thalassemia.
    Festa RS
    Indian J Pediatr; 1987; 54(3):379-89. PubMed ID: 3301658
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: Blood transfusion and iron overload.
    Br Med J; 1975 Nov; 4(5991):244-5. PubMed ID: 1192008
    [No Abstract]   [Full Text] [Related]  

  • 17. Total management of thalassaemia major.
    Modell B
    Arch Dis Child; 1977 Jun; 52(6):489-500. PubMed ID: 879834
    [No Abstract]   [Full Text] [Related]  

  • 18. Intensive iron-chelation in thalassaemia.
    Br Med J; 1978 Sep; 2(6140):782-3. PubMed ID: 698731
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term desferrioxamine therapy in thalassemia.
    Modell CB; Beck J
    Ann N Y Acad Sci; 1974; 232(0):201-10. PubMed ID: 4528634
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.